tradingkey.logo

ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

ReutersMay 23, 2025 12:49 PM

- Gilead Sciences Inc GILD.O:

  • ASCENT-03: TRODELVY® DEMONSTRATES HIGHLY STATISTICALLY SIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHO ARE NOT CANDIDATES FOR CHECKPOINT INHIBITORS

  • GILEAD SCIENCES INC - ASCENT-03 STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN PFS

  • GILEAD SCIENCES INC - TRODELVY SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES IN ASCENT-03

  • GILEAD SCIENCES INC - NO OS DETRIMENT OBSERVED IN ASCENT-03 STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI